Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01968109
Title Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

hepatocellular carcinoma

urinary bladder cancer

head and neck cancer

colorectal cancer

melanoma

lung non-small cell carcinoma

ovarian cancer

cervical cancer

stomach cancer

Therapies

Nivolumab + Relatlimab

Relatlimab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.